Targeting of Mevalonate-Isoprenoid Pathway in Acute Myeloid Leukemia Cells by Bisphosphonate Drugs

• Published in: Biomedicines Vol. 10; no. 5; p. 1146
• Main Authors: Chiarella, Emanuela, Nisticò, Clelia, Di Vito, Anna, Morrone, Helen Linda, Mesuraca, Maria
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 16.05.2022; MDPI
• Subjects: Acute myeloid leukemia; Amino acids; AML; Antitumor activity; Biosynthesis; Bisphosphonates; Cancer; Cancer therapies; Cell survival; Chemotherapy; Cholesterol; Drugs; Enzymes; Farnesyl pyrophosphate synthase; Feedback; Glucose; Glucose metabolism; Homeostasis; Hypoxia; Kinases; Leukemia; Lipid metabolism; Lipids; Low density lipoprotein; Membrane ruffling; Membrane trafficking; Metabolism; Metastases; Metastasis; Mevalonate pathway; Mevalonic acid; Multiple myeloma; Ovaries; Progenitor cells; protein isoprenylation; Proteins; Regulation; Respiration; Review; Signal transduction; small GTPases; Statins; Stem cells; Sterols; Tumorigenesis; Zoledronic acid; AML; bisphosphonates; protein isoprenylation; mevalonate pathway; small GTPases
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10051146

Metabolic reprogramming represents a hallmark of tumorigenesis to sustain survival in harsh conditions, rapid growth and metastasis in order to resist to cancer therapies. These metabolic alterations involve glucose metabolism, known as the Warburg effect, increased glutaminolysis and enhanced amino acid and lipid metabolism, especially the cholesterol biosynthesis pathway known as the mevalonate pathway and these are upregulated in several cancer types, including acute myeloid leukemia (AML). In particular, it was demonstrated that the mevalonate pathway has a pivotal role in cellular transformation. Therefore, targeting this biochemical process with drugs such as statins represents a promising therapeutic strategy to be combined with other anticancer treatments. In the last decade, several studies have revealed that amino-bisphosphonates (BP), primarily used for bone fragility disorders, also exhibit potential anti-cancer activity in leukemic cells, as well as in patients with symptomatic multiple myeloma. Indeed, these compounds inhibit the farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway, reducing isoprenoid formation of farnesyl pyrophosphate and geranylgeranyl pyrophosphate. This, in turn, inhibits the prenylation of small Guanosine Triphosphate-binding proteins, such as Ras, Rho, Rac, Rab, which are essential for regulating cell survival membrane ruffling and trafficking, interfering with cancer key signaling events involved in clonal expansion and maturation block of progenitor cells in myeloid hematological malignancies. Thus, in this review, we discuss the recent advancements about bisphosphonates' effects, especially zoledronate, analyzing the biochemical mechanisms and anti-tumor effects on AML model systems. Future studies will be oriented to investigate the clinical relevance and significance of BP treatment in AML, representing an attractive therapeutic strategy that could be integrated into chemotherapy.